+
Site Tour
SURGICAL
VALVE SOLUTIONS
EPIC™ PLUS MITRAL AND AORTIC STENTED TISSUE VALVES

 

The latest generation of the Epic™ Platform continues the Epic product family’s history of excellence. The future-forward design of the Epic Plus mitral and aortic valves gives you and your patients more choices when it comes to preserving long-term treatment paths.

THE PLATFORM FOR POSSIBILITY

The Epic™ Platform has been proven over time and defined by strong hemodynamics, intuitive implantability, a future-forward design, and more. The platform boasts the low ventricular protrusion in all valve sizes, a flexible polymer stent, individually selected porcine leaflets to ensure optimal coaptation, and a flexible sewing cuff designed to minimize both in-implant suture drag and post-implant paravalvular leak.

Epic™ Plus Supra Aortic Stented Tissue Valve Features
  • Silicone-Filled Cuff
  • FlexFitTM Polymer Stent
  • Unique Pericardial Shield
  • Flexible Cuff
  • Low Stent Post Height

  • Allows for supra-annular implantation

    • Withstands approximately 8 atm pressure during balloon valvuloplasty procedures1
    • Eases implant
    • Accommodates MIS procedures

  • Provides a tissue-to-tissue interface to help prevent the risk of abrasion

  • Mitigates PVL and easily fits patient anatomy

  • Mitigates risk of coronary obstruction

EPIC™ SUPRA AORTIC STENTED TISSUE VALVE FEATURES

Epic Plus Supra aortic stented tissue valve features
1
2
3
4
5

  1. SILICONE-FILLED CUFF

    Allows for supra-annular implantation

  2. FLEXFIT™ POLYMER STENT

    • Withstands approximately 8 atm pressure during balloon valvuloplasty procedures1
    • Eases implant
    • Accommodates MIS procedures.

  3. UNIQUE PERICARDIAL SHIELD

    Provides a tissue-to-tissue interface to help prevent the risk of abrasion

  4. FLEXIBLE CUFF

    Mitigates PVL and easily fits patient anatomy

  5. LOW STENT POST HEIGHT

    Mitigates risk of coronary obstruction

Epic Plus Mitral Stented Tissue Valve Features
  • Optimal Leaflet Design and Matching
  • Low Ventricular Protrusion
  • FlexFitTM Polymer Stent
  • Unique Pericardial Shield
  • Flexible Cuff
  • Ratcheting Holder

  • Reduces regurgitation risk

  • Avoids LVOT obstruction

    • Withstands approximately 8 atm pressure during balloon valvuloplasty procedures1
    • Eases implant
    • Accommodates MIS procedures.

  • Provides a tissue-to-tissue interface to help prevent the risk of abrasion

  • Mitigates PVL and easily fits patient anatomy

  • Streamlines implant and reduces risk of suture looping

EPIC™ MITRAL STENTED TISSUE VALVE FEATURES

Epic Plus Supra mitral stented tissue valve features
1
2
3
4
5
6

  1. OPTIMAL LEAFLET DESIGN AND MATCHING

    Reduces regurgitation risk

  2. LOW VENTRICULAR PROTRUSION

    Avoids LVOT obstruction

  3. FLEXFIT™ POLYMER STENT

    • Withstands approximately 8 atm pressure during balloon valvuloplasty procedures1
    • Eases implant
    • Accommodates MIS procedures.

  4. UNIQUE PERICARDIAL SHIELD

    Provides a tissue-to-tissue interface to help prevent the risk of abrasion

  5. FLEXIBLE CUFF

    Mitigates PVL and easily fits patient anatomy

  6. RATCHETING HOLDER

    Streamlines implant, reduces risk of suture looping, and offers true one cut holder release

Low Profile Design for Now and Later

Curtaining is a characteristic of bioprosthetic valves in which the leaflets, when opened, stand tall or form a “curtain” between stent posts.10,* Epic/Epic Plus Mitral leaflets are not prone to curtaining, which can result in less LVOT obstruction.10,*,†
 

Leaflet behavior when opened

25 mm Epic Mitral† valve (left) and Magna Mitral Ease‡ (right), with representative rods inserted

*Results based on internal testing.
†The Epic and Epic Plus valves are designed to the same specifications for dimension and tissue behavior.
‡Indicates a third-party trademark, which is property of its respective owner.

Preserving the LVOT
Anticalcification advantages

Abbott’s unique Linx™ AC technology—to promote anticalcification*—is designed to improve long-term performance and valve durability.
The Linx™ AC treatment has demonstrated resistance to calcification by:

  • Extracting lipids6
  • Reducing free aldehydes7,8
  • Minimizing cholesterol uptake9
  • Stabilizing leaflet collagen9

*No clinical data currently available has evaluated the long-term impact of AC tissue treatment in humans.

BRINGING YOU...

Clinical Case clubs | Educational tools | Hot topics
Expert opinions | Live & online discussions
 

TV

Early outcomes on Epic Max platform

Cleveland clinic (US) experience: Early outcomes and a perspective on porcine vs. bovine

EACTS 2024 - Novel approaches for Valvular and LVAD therapies

Reconsidering current approaches to valve and LVAD therapies

Epic™ HCP testimonial

Epic™ Mitral & Supra Aortic stented tissue valves HCP testimonial

Epic™ Mitral Valve

Epic™ Mitral stented tissue valve with Linx™ AC technology

Webinar: Aortic & Mitral Valve Disease

Webinar 2022: Management of aortic and mitral valve disease

EACTS 2022: SMV repair vs replacement

EACTS 2022 Symposium: Surgical Mitral Valve Repair versus Replacement in the Modern Era of Transcatheter Valve Interventions.

References
  1.  Guler N, Ozkara C, Akyol A. Left ventricular outflow tract obstruction after bioprosthetic mitral valve replacement with posterior mitral leaflet preservation. Tex Heart Inst J. 2006;33(3):399-401.
  2. Epic Plus Instructions for Use.
  3. Allen KB, Adnan CK, Cohen DJ, et al. Bioprosthetic valve fracture to facilitate transcatheter valve-in-valve implantation. Ann Thorac Surg. 2017;104:1501-1508.
  4. Edelmann JJ, Khan JM, Rogers T, et al. Valve-in-valve TAVR: state-of-the-art review. Innovations. 2019;14(4):299-310.
  5. Jawad, Khalil, Sven Lehmann, Alex Koziarz, Maja Dieterlen, Stefan Feder, Martin Misfeld, Jens Garbade, Vivek Rao, and Michael Borger. "Midterm results after St Jude Medical Epic porcine xenograft for aortic, mitral, and double valve replacement." Journal of Cardiac Surgery 35, no. 8 (2020): 1769-1777.
  6. Adams DH, Rosenhek R, and Falk V. Degenerative mitral valve regurgitation: best practice revolution. Eur Heart J. 2010;31(16):1958-1967. doi:10.1093/eurheartj/ehq222.
  7. Otto, Catherine M., Rick A. Nishimura, Robert O. Bonow, Blase A. Carabello, John P. Erwin III, Federico Gentile, Hani Jneid et al. "2020 ACC/AHA guideline for the management of patients with valvular heart disease: executive summary: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines." Journal of the American College of Cardiology 77, no. 4 (2021): 450-500.
  8. Nishimura RA, Otto CM, Bonow RO, et al. 2014 AHA/ACC Guideline for the management of patients with valvular heart disease. Circulation. 2014;129(23):2240-2492.
  9. Mick SL, Keshavamurthy S, Gillinov AM. Mitral valve repair vs replacement for the management of valvular heart disease. Eur Heart J. 2017;38:2739-2791.
  10. Tests performed by and data on file at Abbott.
  11. Magna Mitral Ease Instructions for Use.
  12. Medtronic Mosaic Bioprosthesis Aortic and Mitral Brochure. #UC200103933b EN.
  13. Vyavahare, N, Hirsch, D, Lerner, E, et al. Prevention of bioprosthetic heart valve calcification by ethanol preincubation. Circulation. 1997:95;479-488. doi.org/10.1161/01.CIR.95.2.479.
  14. Kelly SJ, Ogle MF, Carlyle WC, et al. Biocompatibility and calcification of bioprosthetic heart valves. Presented at: Society for Biomaterials, Sixth World Biomaterials Congress Transaction. May 2000:1353.
  15. Frater RWM, Seifter E, Liao K, et al. Chapter 8. In: Gabbay, S, Wheatley DJ, eds. Advances in Anticalcific and Antidegenerative Treatment of Heart Valve Bioprostheses. 1st ed. Silent Partners, Inc; 1997:105-113.
  16. Vyavahare NR, Hirsch D, Lerner E, et al. Prevention of calcification of glutaraldehyde-crosslinked porcine aortic cusps by ethanol preincubation: mechanistic studies of protein structure and water-biomaterial relationships. J Biomed Mater Res. 1998;40:577-585. doi.org/10.1177/1556984519858020.

 

© Abbott 2024. All rights reserved. 9-EH-5-15002-01 11-2024 REV A

You are about to leave my-connext.com

You are now leaving my-connext.com. Abbott is not responsible for any content published on the third-party website you are about to enter. Abbott has not reviewed and does not endorse any information presented on third-party websites.

The content on this website is intended for healthcare professionals in EMEA with applicable health authority product registrations, excepted those practicing in France as some of the content is not in compliance with the French Advertising law N°2011-2012 dated 29th December 2011 article 34. Click OK to confirm you are a healthcare professional to proceed.

OK Decline